Functional characterization of breast cancer using pathway profiles

BMC Medical Genomics

Volumn 7, Issue 1, 2014, Pages

  Tian, Feng ^a   Wang, Yajie ^b   Seiler, Michael ^a   Hu, Zhenjun ^a  

^a BOSTON UNIVERSITY   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Enrichment analysis; Pathway; Pathway profile; Signature genes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

BIOLOGY; BREAST TUMOR; DNA MICROARRAY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; SEQUENCE ANALYSIS; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; SEQUENCE ANALYSIS, RNA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84904445867     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-7-45     Document Type: Article

References (95)

1. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Loscalzo J, Kohane I, Barabasi AL, Mol Syst Biol 2007 3 124
2. Medicine. The ultimate model organism. Butte AJ, Science 2008 320 325 327
3. Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Itadani H, Mizuarai S, Kotani H, Curr Genomics 2008 9 349 360
4. Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data. Liu JG, Campen A, Huang SG, Peng SB, Ye X, Palakal M, Dunker AK, Xia YN, Li SY, BMC Med Genet 2008 1 39
5. Molecular portraits of human breast tumours. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D, Nature 2000 406 747 752
6. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL, Proc Natl Acad Sci U S A 2001 98 10869 10874 (Pubitemid 32878711)
7. A gene-expression signature as a predictor of survival in breast cancer. van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R, N Engl J Med 2002 347 1999 2009 (Pubitemid 35461656)
8. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Bandres E, Malumbres R, Cubedo E, Honorato B, Zarate R, Labarga A, Gabisu U, Sola JJ, Garcia-Foncillas J, Oncol Rep 2007 17 1089 1094
9. A five-gene signature and clinical outcome in non-small-cell lung cancer. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, Yang PC, N Engl J Med 2007 356 11 20 (Pubitemid 46041749)
10. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, Rowland CM, Catanese JJ, Leong DU, Sninsky JJ, Layden TJ, Wright TL, White T, Cheung RC, Hepatology 2007 46 297 306 (Pubitemid 47344763)
11. Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis. Okahara S, Arimura Y, Yabana T, Kobayashi K, Gotoh A, Motoya S, Imamura A, Endo T, Imai K, Aliment Pharmacol Ther 2005 21 1091 1097 (Pubitemid 40646534)
12. Why most gene expression signatures of tumors have not been useful in the clinic. Koscielny S, Sci Transl Med 2010 2 14ps12
13. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J, J Clin Oncol 2013 31 2783 2790
14. Outcome signature genes in breast cancer: is there a unique set? Ein-Dor L, Kela I, Getz G, Givol D, Domany E, Bioinformatics 2005 21 171 178 (Pubitemid 40202018)
15. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Ein-Dor L, Zuk O, Domany E, Proc Natl Acad Sci U S A 2006 103 5923 5928
16. Reliability and reproducibility issues in DNA microarray measurements. Draghici S, Khatri P, Eklund AC, Szallasi Z, Trends Genet 2006 22 101 109 (Pubitemid 43152029)
17. Network biology: understanding the cell's functional organization. Barabasi AL, Oltvai ZN, Nat Rev Genet 2004 5 101 113 (Pubitemid 38160277)
18. Gene expression profiling predicts clinical outcome of breast cancer. van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH, Nature 2002 415 530 536 (Pubitemid 34130608)
19. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA, Lancet 2005 365 671 679 (Pubitemid 40260888)
20. Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? Drier Y, Domany E, Plos One 2011 6 3 17795
21. The modular nature of genetic diseases. Oti M, Brunner HG, Clin Genet 2007 71 1 11 (Pubitemid 44921616)
22. Statistical aspects of gene signatures and molecular targets. Gonen M, Gastrointest Cancer Res 2009 3 19 S21
23. Approaches to complex pathways in molecular epidemiology: summary of a Special Conference of the American Association for Cancer Research. Thomas DC, Baurley JW, Brown EE, Figueiredo JC, Goldstein A, Hazra A, Wilson RT, Rothman N, Cancer Res 2008 68 10028 10030
24. Making sense of cancer genomic data. Chin L, Hahn WC, Getz G, Meyerson M, Genes Dev 2011 25 534 555
25. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR, Genome Biol 2003 4 7
26. A module map showing conditional activity of expression modules in cancer. Segal E, Friedman N, Koller D, Regev A, Nat Genet 2004 36 1090 1098 (Pubitemid 41184471)
27. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Bild AH, Yao G, Chang JT, Wang QL, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR, Nature 2006 439 353 357 (Pubitemid 43128862)
28. Pathway Analysis of expression data: deciphering functional building blocks of complex diseases. Emmert-Streib F, Glazko GV, Plos Comput Biol 2011 7 1002053
29. Pathway information for systems biology. Cary MP, Bader GD, Sander C, FEBS Letters 2005 579 1815 1820 (Pubitemid 40342658)
30. Pathway-based classification of cancer subtypes. Kim S, Kon M, DeLisi C, Biol Direct 2012 7 21
31. Identification of functional modules that correlate with phenotypic difference: the influence of network topology. Hung JH, Whitfield TW, Yang TH, Hu Z, Weng Z, DeLisi C, Genome Biol 2010 11 23
32. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Proc Natl Acad Sci U S A 2005 102 15545 15550 (Pubitemid 41528093)
33. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu JC, Haussler D, Stuart JM, Bioinformatics 2010 26 237 i245
34. Pathway-based personalized analysis of cancer. Drier Y, Sheffer M, Domany E, Proc Natl Acad Sci U S A 2013 110 6388 6393
35. Comprehensive molecular portraits of human breast tumours. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YSN, Carlsen R, Carter C, Chu A, Chuah E, Chun HJE, Coope RJN, Dhalla N, Guin R, Hirst C, Hirst M, Holt RA, Lee D, Li HYI, Mayo M, Moore RA, Mungall AJ, et al. Nature 2012 490 61 70
36. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, et al. Nature 2012 486 346 352
37. Integrated genomic analyses of ovarian carcinoma. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, Iacocca M, Imielinski M, Kalloger S, Karlan BY, Levine DA, Mills GB, Morrison C, Mutch D, Olvera N, Orsulic S, Park K, Petrelli N, Rabeno B, Rader JS, Sikic BI, et al. Nature 2011 474 609 615
38. KEGG: kyoto encyclopedia of genes and genomes. Kanehisa M, Goto S, Nucleic Acids Res 2000 28 27 30 (Pubitemid 30047706)
39. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, Zhu J, Sci Rep 2013 3 2652
40. Gene set enrichment analysis: performance evaluation and usage guidelines. Hung JH, Yang TH, Hu ZJ, Weng ZP, DeLisi C, Brief Bioinform 2012 13 281 291
41. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, Harris L, Barnard N, Martel M, Levine AJ, Ganesan S, Bhanot G, Cancer Res 2007 67 10669 10676 (Pubitemid 350145892)
42. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A, Cancer Treat Rev 2012 38 698 707
43. Concordance among gene-expression-based predictors for breast cancer. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van't Veer LJ, Perou CM, N Engl J Med 2006 355 560 569 (Pubitemid 44200649)
44. Controlling the false discovery rate-a practical and powerful approach to multiple testing. Benjamini Y, Hochberg Y, J R Stat Soc Ser B-Methodological 1995 57 289 300
45. Microarray platform consistency is revealed by biologically functional analysis of gene expression profiles. Li ZG, Su ZQ, Wen ZN, Shi LM, Chen T, BMC Bioinformatics 2009 10 Suppl 11 12
46. Network-based classification of breast cancer metastasis. Chuang HY, Lee E, Liu YT, Lee D, Ideker T, Mol Syst Biol 2007 3 140
47. RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y, Genome Res 2008 18 1509 1517
48. RNA-Seq: a revolutionary tool for transcriptomics. Wang Z, Gerstein M, Snyder M, Nat Rev Genet 2009 10 57 63
49. Ten Years of pathway analysis: current approaches and outstanding challenges. Khatri P, Sirota M, Butte AJ, Plos Comput Biol 2012 8 1002375
50. Links between metabolism and cancer. Dang CV, Genes Dev 2012 26 877 890
51. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. Fernadez V, Hartmann E, Ott G, Campo E, Rosenwald A, J Clin Oncol 2005 23 6364 6369 (Pubitemid 46218848)
52. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, et al. Science 2008 321 1801 1806
53. Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis. Pham L, Christadore L, Schaus S, Kolaczyk ED, Proc Natl Acad Sci U S A 2011 108 13347 13352
54. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Cully M, You H, Levine AJ, Mak TW, Nat Rev Cancer 2006 6 184 192 (Pubitemid 43292562)
55. Notch signaling pathway as a therapeutic target in breast cancer. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS, Mol Cancer Ther 2011 10 9 15
56. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Osborne CK, Shou J, Massarweh S, Schiff R, Clin Cancer Res 2005 11 865s 870s (Pubitemid 40111098)
57. Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. Yu ZR, Wang LP, Wang CG, Ju XM, Wang M, Chen K, Loro E, Li ZP, Zhang YZ, Wu KM, Casimiro MC, Gormley M, Ertel A, Fortina P, Chen YH, Tozeren A, Liu ZM, Pestell RG, Nat Commun 2013 4 2812
58. Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Pontano LL, Aggarwal P, Barbash O, Brown EJ, Bassing CH, Diehl JA, Mol Cell Biol 2008 28 7245 7258
59. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis JS, Dowsett M, Ashworth A, Turner NC, Clin Cancer Res 2010 16 6159 6168
60. Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, Valgeirsdottir S, Eyfjord JE, Breast Cancer Res 2011 13 95
61. Metabotropic glutamate receptor-1 is oncogenic in triple-negative breast cancer. Banda M, Speyer C, Gorski D, Ann Surg Oncol 2012 19 23 23
62. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue-a GC-TOFMS based metabolomics study. Budczies J, Denkert C, Muller BM, Brockmoller SF, Klauschen F, Gyorffy B, Dietel M, Richter-Ehrenstein C, Marten U, Salek RM, Griffin JL, Hilvo M, Oresic M, Wohlgemuth G, Fiehn O, BMC Genomics 2012 13 334
63. ErbB receptors and signaling pathways in cancer. Hynes NE, MacDonald G, Curr Opin Cell Biol 2009 21 177 184
64. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG, Carcinogenesis 2005 26 1241 1246
65. Gene annotation and network inference by phylogenetic profiling. Wu J, Hu Z, DeLisi C, BMC Bioinformatics 2006 7 80
66. Gitools: analysis and visualisation of genomic data using interactive heat-maps. Perez-Llamas C, Lopez-Bigas N, Plos One 2011 6 19541
67. Analyzing networks with VisANT. Hu Z, Mellor J, DeLisi C, Curr Protoc Bioinformatics 2004 8 Chapter 8:Unit 8.8.1-24
68. VisANT: an online visualization and analysis tool for biological interaction data. Hu Z, Mellor J, Wu J, DeLisi C, BMC Bioinformatics 2004 5 17
69. VisANT 3.0: new modules for pathway visualization, editing, prediction and construction. Hu Z, Ng DM, Yamada T, Chen C, Kawashima S, Mellor J, Linghu B, Kanehisa M, Stuart JM, DeLisi C, Nucleic Acids Res 2007 35 625 W632
70. VisANT: an integrative framework for networks in systems biology. Hu Z, Snitkin ES, DeLisi C, Brief Bioinform 2008 9 317 325 (Pubitemid 351890828)
71. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies. Hu Z, Chang YC, Wang Y, Huang CL, Liu Y, Tian F, Granger B, Delisi C, Nucleic Acids Res 2013 41 225 W231
72. VisANT: data-integrating visual framework for biological networks and modules. Hu Z, Mellor J, Wu J, Yamada T, Holloway D, Delisi C, Nucleic Acids Res 2005 33 352 W357
73. Towards zoomable multidimensional maps of the cell. Hu Z, Mellor J, Wu J, Kanehisa M, Stuart JM, DeLisi C, Nat Biotechnol 2007 25 547 554 (Pubitemid 46834845)
74. VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. Hu Z, Hung JH, Wang Y, Chang YC, Huang CL, Huyck M, DeLisi C, Nucleic Acids Res 2009 37 115 W121
75. Breast cancer: origins and evolution. Polyak K, J Clin Invest 2007 117 3155 3163 (Pubitemid 350096968)
76. Minireview: obesity and breast cancer: the estrogen connection. Cleary MP, Grossmann ME, Endocrinology 2009 150 2537 2542
77. Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks. Piccirilli M, Salvati M, Bistazzoni S, Frati A, Brogna C, Giangaspero F, Frati R, Santoro A, Tumori 2005 91 256 260 (Pubitemid 41076133)
78. Estrogen receptors are identified in the glioblastoma cell line U138MG. Leslie KK, Keefe D, Powell S, Naftolin F, J Soc Gynecol Investig 1994 1 238 244 (Pubitemid 2134397)
79. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. Mineo JF, Bordron A, Baroncini M, Maurage CA, Ramirez C, Siminski RM, Berthou C, Dam Hieu P, J Neurooncol 2007 85 281 287 (Pubitemid 350142517)
80. Leptin promotes glioblastoma. Lawrence JE, Cook NJ, Rovin RA, Winn RJ, Neurol Res Int 2012 2012 870807
81. Identification of functional modules using network topology and high-throughput data. Ulitsky I, Shamir R, BMC Syst Biol 2007 1 8
82. Why do cancers have high aerobic glycolysis? Gatenby RA, Gillies RJ, Nat Rev Cancer 2004 4 891 899 (Pubitemid 39472955)
83. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M, Breast Cancer Res Treat 2008 112 41 52
84. Analyzing the regulation of metabolic pathways in human breast cancer. Schramm G, Surmann EM, Wiesberg S, Oswald M, Reinelt G, Eils R, Konig R, BMC Med Genomics 2010 3 39
85. Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways. Miecznikowski JC, Wang D, Liu S, Sucheston L, Gold D, BMC Cancer 2010 10 573
86. Arginase activity in human breast cancer cell lines: N (omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G, Cancer Res 2000 60 3305 3312 (Pubitemid 30407931)
87. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie JX, Ge QY, Gu TL, Polakiewicz RD, Roesel JL, Chen GZ, Boggon TJ, Lonial S, Fu HA, Khuri FR, Kang SM, Chen J, Mol Cell 2011 44 864 877
88. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. Fong MY, McDunn J, Kakar SS, PLoS One 2011 6 19963
89. One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. Chen J, Gammon MD, Chan W, Palomeque C, Wetmur JG, Kabat GC, Teitelbaum SL, Britton JA, Terry MB, Neugut AI, Santella RM, Cancer Res 2005 65 1606 1614 (Pubitemid 40270191)
90. The Fanconi anemia pathway and ubiquitin. Jacquemont C, Taniguchi T, BMC Biochem 2007 8 Suppl 1 10
91. Exploiting the PI3K/AKT pathway for cancer drug discovery. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB, Nat Rev Drug Discov 2005 4 988 1004
92. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Yamaguchi H, Condeelis J, Biochim BiophysActa 2007 1773 642 652 (Pubitemid 46660177)
93. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. Golubovskaya V, Beviglia L, Xu LH, Earp HS 3rd, Craven R, Cance W, J Biol Chem 2002 277 38978 38987 (Pubitemid 35154764)
94. Adipocytokines and cancer. Housa D, Housova J, Vernerova Z, Haluzik M, Physiol Res 2006 55 233 244
95. The brain within the tumor: new roles for axon guidance molecules in cancers. Chedotal A, Kerjan G, Moreau-Fauvarque C, Cell Death Differ 2005 12 1044 1056 (Pubitemid 41065422)